1. Home
  2. BBY vs GMAB Comparison

BBY vs GMAB Comparison

Compare BBY & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBY
  • GMAB
  • Stock Information
  • Founded
  • BBY 1966
  • GMAB 1999
  • Country
  • BBY United States
  • GMAB Denmark
  • Employees
  • BBY N/A
  • GMAB N/A
  • Industry
  • BBY Consumer Electronics/Video Chains
  • GMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBY Consumer Discretionary
  • GMAB Health Care
  • Exchange
  • BBY Nasdaq
  • GMAB Nasdaq
  • Market Cap
  • BBY 15.6B
  • GMAB 17.4B
  • IPO Year
  • BBY N/A
  • GMAB N/A
  • Fundamental
  • Price
  • BBY $77.78
  • GMAB $29.82
  • Analyst Decision
  • BBY Buy
  • GMAB Strong Buy
  • Analyst Count
  • BBY 19
  • GMAB 6
  • Target Price
  • BBY $82.18
  • GMAB $40.40
  • AVG Volume (30 Days)
  • BBY 3.3M
  • GMAB 2.6M
  • Earning Date
  • BBY 11-25-2025
  • GMAB 11-06-2025
  • Dividend Yield
  • BBY 4.86%
  • GMAB N/A
  • EPS Growth
  • BBY N/A
  • GMAB 132.41
  • EPS
  • BBY 3.63
  • GMAB 25.10
  • Revenue
  • BBY $41,598,000,000.00
  • GMAB $3,845,670,022.00
  • Revenue This Year
  • BBY $1.64
  • GMAB $24.92
  • Revenue Next Year
  • BBY $1.33
  • GMAB $15.97
  • P/E Ratio
  • BBY $21.54
  • GMAB $1.16
  • Revenue Growth
  • BBY N/A
  • GMAB 29.57
  • 52 Week Low
  • BBY $54.99
  • GMAB $17.24
  • 52 Week High
  • BBY $95.49
  • GMAB $33.65
  • Technical
  • Relative Strength Index (RSI)
  • BBY 44.28
  • GMAB 53.13
  • Support Level
  • BBY $76.67
  • GMAB $28.08
  • Resistance Level
  • BBY $82.60
  • GMAB $29.35
  • Average True Range (ATR)
  • BBY 2.08
  • GMAB 0.65
  • MACD
  • BBY -0.76
  • GMAB -0.10
  • Stochastic Oscillator
  • BBY 12.74
  • GMAB 84.51

About BBY Best Buy Co. Inc.

With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: